LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Vanda Pharmaceuticals Inc

Suletud

4.78 -0.83

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.75

Max

4.94

Põhinäitajad

By Trading Economics

Sissetulek

-25M

-29M

Müük

-3.1M

50M

Aktsiakasum

-0.5

Kasumimarginaal

-58.94

Töötajad

368

EBITDA

-23M

-31M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+242.32% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-4.2M

263M

Eelmine avamishind

5.61

Eelmine sulgemishind

4.78

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Vanda Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. juuni 2025, 20:51 UTC

Tulu

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. juuni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. juuni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. juuni 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27. juuni 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. juuni 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27. juuni 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27. juuni 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27. juuni 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. juuni 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. juuni 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27. juuni 2025, 18:39 UTC

Market Talk
Tulu

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27. juuni 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27. juuni 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27. juuni 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27. juuni 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27. juuni 2025, 17:08 UTC

Tulu

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27. juuni 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27. juuni 2025, 16:22 UTC

Tulu

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. juuni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27. juuni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. juuni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27. juuni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27. juuni 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27. juuni 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Vanda Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

242.32% tõus

12 kuu keskmine prognoos

Keskmine 16.5 USD  242.32%

Kõrge 20 USD

Madal 13 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Vanda Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

4.22 / 4.44Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.